Physician profile

Craig E Berger

Ophthalmology · Tampa, FL

NPI 1023031788

$17,038.43

in general payments reported to CMS, 2019-2025

33 companies · $2,843 in 2025

The $2,843 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$6,162.19
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$3,000.00
Consulting Fee$835.00
Honoraria$38.86

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaukos Corporation $6,548.44 2020-2025 Kxl System (Not Refurbished), Photrexa Viscous and Photrexa, Ce-Marked Kxla System
Avedro INC. $2,450.00 2019
Alcon Vision LLC $1,298.54 2019-2025 Clareon, Tryptyr, Acrysof Iq Vivity
Bausch & Lomb Americas INC. $1,045.25 2022-2025 Miebo, Xiidra, Vyzulta
Bausch & Lomb, A Division of Bausch Health US, LLC $690.29 2019-2021
Mallinckrodt Hospital Products INC. $584.71 2021-2025 Acthar
Johnson & Johnson Surgical Vision, INC. $491.76 2019-2023 Tecnis Iol
Sun Pharmaceutical Industries INC. $455.46 2019-2025 Cequa
Oyster Point Pharma, INC. $429.20 2022-2025 Tyrvaya, Ryzumvi, Ryzumvi
Abbvie INC. $376.24 2022-2024 Durysta
Novartis Pharmaceuticals Corporation $366.38 2019-2023
Dompe US, INC. $297.55 2019-2025 Oxervate
Allergan, INC. $285.12 2019-2021
Rxsight INC $261.23 2022-2025 Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens
Kala Pharmaceuticals, INC. $232.50 2019-2021
Show all 33 companies
CompanyGeneral paymentsYearsTop products
Tarsus Pharmaceuticals, INC. $216.38 2024-2025 Xdemvy
Aerie Pharmaceuticals, INC. $198.12 2019-2021
Ani Pharmaceuticals, INC. $145.99 2023-2025 Purified Cortrophin Gel
Shire North American Group INC $103.31 2019
Harrow Eye, LLC $73.93 2024-2025 Vevye, Iheezo
Carl Zeiss Meditec, INC. $64.71 2019
Amgen INC. $62.76 2024-2025 Tepezza
Sight Sciences, INC. $49.75 2021-2025 Tearcare System, Sion Surgical Instrument, Omni Surgical System
Biotissue Holdings INC. $47.79 2019-2025
Ziemer USA $45.57 2025 Femto Ldv, Femtoldv
New World Medical,INC. $41.14 2021-2024 Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline
Lombart Brothers, INC. $40.59 2025 Opd-III
Abb Con-Cise Optical Group LLC $35.78 2019
Rayner Intraocular Lenses Limited $28.13 2025 Omidria
Ocular Therapeutix, INC. $20.95 2022
Eyevance Pharmaceuticals LLC $20.00 2019
Akorn Operating Company LLC $17.30 2021
Alcon Research LLC $13.56 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Craig E Berger

$17,038.43

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaukos Corporation
Context
The $2,843 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).

https://glasscript.com/doctor/1275/craig-e-berger

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.